Novo Nordisk's 2035 Roadmap Fails to Soothe a Market Fixated on Semaglutide's Expiry
Published on 09/24/2026 at 22:30 | Editorial boerse-global.de
Novo Nordisk used its capital markets day to sketch a future that reaches well past semaglutide, but investors were in no mood to look that far ahead. The Danish drugmaker laid out a long-range ambition of risk-adjusted pipeline revenue exceeding DKK 150 billion by 2035, alongside plans to launch several medicines with multi-blockbuster potential before the decade is out. The pitch landed flat. During Monday's session the stock fell as much as 9 percent at one point, and the shares were quoted at EUR 33.35 in the latest trading, down 0.9 percent on the day — a retreat that extends a bruising run of minus 24 percent since the start of the year.
A Wider Therapeutic Map
To underpin that growth, the company intends to broaden its therapeutic footprint. A business long defined by diabetes and obesity treatments is turning its attention toward blood and endocrine disorders as well as liver and cardiovascular disease. Management expects revenue growth between 2026 and 2030 to land in line with the industry peer group. The DKK 150 billion figure, as Reuters reported, is built on internal, risk-adjusted assets and excludes any contribution from future acquisitions. Novo Nordisk has stressed that its balance sheet can absorb larger deals, and it is openly weighing bigger purchases alongside smaller bolt-ons to add momentum.
Analysts Cut, Skepticism Stays
The day after the event, several research houses adjusted their numbers — and the direction was uniformly down. Deutsche Bank trimmed its price target to DKK 245 from DKK 265 while keeping a "Sell" rating. Jefferies followed with a cut to DKK 275 from DKK 285, maintaining "Hold." The reasoning from Jefferies was blunt: the presentations did nothing to clear up the uncertainty surrounding the expiry of semaglutide's patent protection. Investors are focused squarely on future pricing power and the threat of generic competition, and questions linger over how quickly new products can plug any revenue gap left by established ones. Analysts also pushed back on the assumptions behind the company's pricing outlook and the shape of its M&A strategy.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Chinese Approval, and a Date in Milan
Away from the capital markets debate, Novo Nordisk notched an operational win. Wegovy received approval in China on September 10, according to Reuters, making it the first GLP-1 receptor agonist of its class there for treating metabolic dysfunction-associated steatohepatitis (MASH). Whether such regional clearances can offset medium-term growth worries is the question that will shape the share price from here — the market is demanding concrete answers on how the company plans to bridge the patent cliff looming over its key compound. Near-term attention now shifts to clinical data: from September 28 to October 2, Novo Nordisk will present fresh results from its cardiometabolic portfolio at the annual meeting of the European Association for the Study of Diabetes in Milan. The stock, currently 38 percent below its 52-week high, suggests investors will need more than a roadmap to be convinced.
Ad
Novo Nordisk Stock: New Analysis - 24 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
